US4436727A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Refined detoxified endotoxin product
Assignee: Ribi Immunochem Research Inc
•
Filing: 1982-05-26
•
Granted: 1984-03-13
•
Expires: 2002-05-26
Abstract
Abstract A refined detoxified endotoxin (RDE) product is disclosed which, when combined with cell wall skeleton (CWS), results in a composition useful for the treatment of cancerous tumors. Methods of making RDE as well as methods of using the combination of RDE and CWS are also disclosed.
Inventors
- 👤 Edgar E. Ribi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 21:27
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/66; A61K35/74; A61P; A61P35/00; A61P35/02; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/82; Y10S530/825
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
125 words
A method of producing refined detoxified endotoxin having no detectable 2-keto-3-deoxyoctanoate, between about 350 and 475 nmoles/mg of phosphorus, and between about 1700 and 2000 nmoles/mg of fatty acids which comprises: (a) hydrolyzing an endotoxin extract derived from Enterobacteriaciae with an acid capable of hydrolyzing the same; (b) lyophilizing the hydrolyzed product to obtain crude lipid A; (c) treating crude lipid A with a first solvent capable of dissolving fatty acids contained therein to remove said fatty acids from a resulting insoluble product (d) dissolving the resulting insoluble product in a second solvent capable of dissolving the same; and (e) passing the resulting solution through a chromatographic column of a type which will allow elution of the desired product to obtain the refined detoxified endotoxin.
Claim 2
Independent Claim
125 words
A method of producing refined detoxified endotoxin having no detectable 2-keto-3-deoxyoctanoate, between about 350 and 475 nmoles/mg of phosphorus, and between about 1700 and 2000 nmoles/mg of fatty acids which comprises: (a) hydrolyzing an endotoxin extract derived from Enterobacteriaciae with an acid capable of hydrolyzing the same; (b) lyophilizing the hydrolyzed product to obtain crude lipid A; (c) treating crude lipid A with a first solvent capable of dissolving fatty acids contained therein to remove said fatty acids from a resulting insoluble product (d) dissolving the resulting insoluble product in a second solvent capable of dissolving the same; and (e) passing the resulting solution through a chromatographic column of a type which will allow elution of the desired product to obtain the refined detoxified endotoxin.
Claim 3
Dependent Claim
27 words
The method of claim 1 wherein the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, toluene sulfonic acid, and trichloroacetic acid.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein the first solvent is acetone.
Claim 5
Dependent Claim
32 words
The method of claim 1 wherein the second solvent is at least one member selected from the group consisting of methanol, chloroform, acetone, pyridine, ether and acetic acid, and a mixture thereof.
Claim 6
Dependent Claim
19 words
The method of claim 1 wherein the reaction is conducted at a temperature between about 90° and 130° C.
Claim 7
Dependent Claim
32 words
Refined detoxified endotoxin having no detectable 2-keto-3-deoxyoctanoate, between about 350 and 475 nmoles/mg of phosphorus and between about 1700 and 2000 nmoles/mg of fatty acids prepared by the method of claim 1.
Claim 8
Dependent Claim
31 words
A therapeutic composition for imparting immunotherapy comprising an effective amount of the refined detoxified endotoxin product according to claim 6 in combination with cell wall skeleton and a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
13 words
The composition of claim 7 wherein the composition is in a lyophilized form.
Claim 10
Dependent Claim
13 words
The composition of claim 7 in the form of an oil droplet emulsion.
Claim 11
Dependent Claim
38 words
The composition of claim 7 wherein the therapeutically effective amount of refined detoxified endotoxin is up to about 1500 micrograms per injection and the effective amount of cell wall skeleton is up to about 4500 micrograms per injection.
Claim 12
Dependent Claim
30 words
A method for imparting immunotherapy in a warm-blooded animal having an immunogenic tumor comprising administering the composition of claim 7 into said warm-blooded animal by injection into said immunogenic tumor.
Claim 13
Dependent Claim
32 words
The method of claim 11 further comprising administering said composition containing between about 6.25 and 250 micrograms/ml of refined detoxified endotoxin and between about 125 and 750 micrograms/ml of cell wall skeleton.
Claim 14
Dependent Claim
17 words
The method of claim 12 wherein said injections are made at intervals of at least one week.
Claim 15
Dependent Claim
28 words
The method of claim 1, wherein the Enterobacteriaciae are selected from the group consisting of Salmonella, Shigella, Escherichia, Brucella, Bordetella, Citrobacter, Pseudomonas, Pasturella, Neisseria, Proteus, Klebsiella, and Serratia.
Claim 16
Dependent Claim
29 words
The method of claim 14, wherein the Enterobacteriaciae are selected from the group consisting of S.minnesota, S.typhimurium, B.pertussis, B.abortus, S.enteritidis, E.coli, S.typhi, S.marcescens, S.typhosa, Shigella flexni, and S.abortus equi.
Claim 17
Dependent Claim
14 words
The method of claim 1, wherein the endotoxin extract is obtained by methanol-chloroform precipitation.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-03-13 | 1987-09-12 | 1988-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-03-13 | 1991-09-12 | 1992-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-03-13 | 1995-09-12 | 1996-03-13 | $7700.00 | Window Closed / Lapsed |